What is claimed is:

1. A method of treating steroid responsive dermatoses in a mammal in need thereof which comprises administering a therapeutically effective amount of a compound selected from: *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof; and *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof; to such mammal.

2. The method of claim 1 wherein the mammal is a human.

3. The method of claim 2 wherein the administered compound is *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof.

4. The method of claim 2 wherein the administered compound is *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.

5. The method of claim 2 wherein the administered compound is *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide.

6. The method claim 2 wherein the administered compound is *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 wherein the steroid responsive dermatoses is selected from: contact dermatitis, eczema, infantile eczema, atopic dermatitis, ichthyosis, psoriasis, xeroderma, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, neurodermatitis, stasis dermatitis, lichen simplex chronicus, dermatophytids, candidiasis, intertrigo, scabies, pityriasis rosea, lichen planus, pityriasis rubra pilaris, bullous pemphigoid, miliaria, acute and chronic eczema, lupus erythematosis, photoallergic reactions, pruritis, and combinations thereof.

8. The method of claim 7 wherein the steroid responsive dermatoses is psoriasis.

9. The method of claim 7 wherein the compound is administered orally.

10. The method of claim 7 wherein the compound is administered topically.

11. The method of claim 7 wherein the mammal is a human.

12. A method of treating steroid responsive dermatoses in a mammal in need thereof, which comprises: administering to such mammal a therapeutically effective amount of

a) *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof; and

b) at least one additional agent known to treat steroid responsive dermatoses.

13. A pharmaceutical combination as claimed in claim 12 for use in therapy.

14. The use of a pharmaceutical combination as claimed in claim 12 for the preparation of a medicament useful in the treatment of steroid responsive dermatoses.

15. Use of *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of steroid responsive dermatoses.

16. A pharmaceutical composition for use in the treatment of steroid responsive dermatoses in mammals comprising *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof.

17. The method of claim 10 wherein the mammal is a human.

18. A pharmaceutical composition suitable for topical administration comprising *N*-{(1*S*)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof.

19. A method of treating steroid responsive dermatoses in a mammal in need thereof, which comprises: administering to such mammal a therapeutically effective amount of

a) *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof; and

b) at least one additional agent known to treat steroid responsive dermatoses.

20. The use of a compound as claimed in claim 1 for the preparation of a medicament useful in the treatment of steroid responsive dermatoses.

21. Use of *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of steroid responsive dermatoses.

22. A pharmaceutical combination as claimed in claim 19 for use in therapy.

23. The use of a pharmaceutical combination as claimed in claim 19 for the preparation of a medicament useful in the treatment of steroid responsive dermatoses.

24. A pharmaceutical composition suitable for topical administration comprising *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof.

25. The method claim 2 wherein the administered compound is *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide.

26. A pharmaceutical composition for use in the treatment of steroid responsive dermatoses in mammals comprising *N*-{(1*S*)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1*H*-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof.

Claims

1 Use of a compound selected from: N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof; and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof; in the manufacture of a medicament for the treatment of steroid responsive dermatoses.

2 Use of claim 1, wherein the compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof.

3 Use of claim 1, wherein the compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.

4 Use of claim 1, wherein the compound is N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide.

5 Use of claim 1, wherein the compound is N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide or a pharmaceutically acceptable salt thereof.

6 Use of

a) N-{(1S)-2-Amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide or a pharmaceutically acceptable salt thereof; and

b) at least one additional agent known to treat steroid responsive dermatoses in the manufacture of a medicament for the treatment of steroid responsive dermatoses.

7 Use of any one of claims 1 to 6 wherein the steroid responsive dermatoses is selected from: contact dermatitis, eczema, infantile eczema, atopic dermatitis, ichthyosis, psoriasis, xeroderma, seborrheic dermatitis, nummular dermatitis, dermatitis herpetiformis, neurodermatitis, stasis dermatitis, lichen simplex chronicus, dermatophytids, candidiasis, intertrigo, scabies, pityriasis rosea, lichen planus, pityriasis rubra pilaris, bullous pemphigoid, miliaria, acute and chronic eczema, lupus erythematosis, photoallergic reactions, pruritis, and combinations thereof.

8 Use of any one of claims 1 to 7 wherein the medicament is formulated for oral administration.

9 Use of any one of claims 1 to 7 wherein the medicament is formulated for topical administration.